Companies / Sutro Biopharma, Inc. / Activity
Activity — Sutro Biopharma, Inc.
46 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | Chow Gregory K. Executive | Exercise | Common Stock | $0 | +3K +112.36% | 4,725 0.03% of shares | low |
| Mar 4, 2026 | Pauling David Executive | Exercise | Common Stock | $0 | +675 +7.22% | 10,025 0.06% of shares | low |
| Mar 4, 2026 | Chung Jane CEO | Exercise | Common Stock | $0 | +788 +3.79% | 21,567 0.13% of shares | low |
| Mar 2, 2026 | Pauling David Executive | Exercise | Common Stock | $0 | +2K +29.58% | 10,320 0.06% of shares | low |
| Mar 1, 2026 | Pauling David Executive | Exercise | Common Stock | $0 | +842 +10.97% | 8,515 0.05% of shares | low |
| Mar 1, 2026 | Pauling David Executive | Exercise | Common Stock | $0 | +500 +6.97% | 7,673 0.05% of shares | low |
| Mar 2, 2026 | Gerber Hans-Peter Executive | Exercise | Common Stock | $0 | +3K +36.24% | 10,688 0.06% of shares | low |
| Mar 1, 2026 | Gerber Hans-Peter Executive | Exercise | Common Stock | $0 | +1K +15.66% | 8,308 0.05% of shares | low |
| Mar 2, 2026 | Chung Jane CEO | Exercise | Common Stock | $0 | +8K +49.03% | 23,558 0.14% of shares | low |
| Mar 1, 2026 | Chung Jane CEO | Exercise | Common Stock | $0 | +3K +17.15% | 17,079 0.10% of shares | low |
| Mar 1, 2026 | Chung Jane CEO | Exercise | Common Stock | $0 | +688 +4.95% | 14,579 0.09% of shares | low |
| Mar 4, 2026 | Pauling David Executive | Other | Common Stock | $5.9K | -277 -2.76% | 9,748 0.06% of shares | low |
| Mar 4, 2026 | Chung Jane CEO | Other | Common Stock | $6.0K | -282 -1.31% | 21,285 0.13% of shares | low |
| Mar 1, 2026 | Gerber Hans-Peter Executive | Other | Common Stock | $9.5K | -463 -5.57% | 7,845 0.05% of shares | low |
| Mar 1, 2026 | Pauling David Executive | Other | Common Stock | $11.3K | -551 -6.47% | 7,964 0.05% of shares | low |
| Mar 2, 2026 | Pauling David Executive | Other | Common Stock | $19.9K | -970 -9.40% | 9,350 0.06% of shares | low |
| Mar 2, 2026 | Gerber Hans-Peter Executive | Other | Common Stock | $24.0K | -1K -10.95% | 9,518 0.06% of shares | low |
| Mar 1, 2026 | Chung Jane CEO | Other | Common Stock | $26.0K | -1K -7.44% | 15,808 0.10% of shares | low |
| Mar 2, 2026 | Chung Jane CEO | Other | Common Stock | $57.1K | -3K -11.80% | 20,779 0.13% of shares | low |
| Jun 5, 2026 | Hunter Heidi Director | Grant | Stock Option (right to buy) | — | +10K | 10,000 0.06% of shares | low |
| Jun 5, 2026 | Dybbs Michael Director | Grant | Stock Option (right to buy) | — | +10K | 10,000 0.06% of shares | low |
| Jun 5, 2026 | Wigginton Jon Marc Director | Grant | Stock Option (right to buy) | — | +10K | 10,000 0.06% of shares | low |
| Jun 5, 2026 | Jagpal Sukhi Director | Grant | Stock Option (right to buy) | — | +10K | 10,000 0.06% of shares | low |
| Jun 5, 2026 | Lobacki Joseph M Director | Grant | Stock Option (right to buy) | — | +10K | 10,000 0.06% of shares | low |
| Jun 2, 2026 | Chow Gregory K. Executive | Exercise | Restricted Stock Units (RSUs) | — | -3K -25.00% | 7,500 0.05% of shares | low |
| Jun 5, 2026 | Petree Daniel H Director | Grant | Stock Option (right to buy) | — | +10K | 10,000 0.06% of shares | low |
| Jun 5, 2026 | Matsui Connie Director | Grant | Stock Option (right to buy) | — | +10K | 10,000 0.06% of shares | low |
| Jun 5, 2026 | Panek James P Director | Grant | Stock Option (right to buy) | — | +10K | 10,000 0.06% of shares | low |
| Mar 2, 2026 | Chow Gregory K. Executive | Grant | Restricted Stock Units (RSUs) | — | +5K | 5,000 0.03% of shares | low |
| Mar 2, 2026 | Chow Gregory K. Executive | Grant | Stock Option (right to buy) | — | +40K | 40,000 0.24% of shares | low |
| Mar 4, 2026 | Pauling David Executive | Exercise | Restricted Stock Units (RSUs) | — | -675 -100.00% | 0 0.00% of shares | low |
| Mar 4, 2026 | Chung Jane CEO | Exercise | Restricted Stock Units (RSUs) | — | -788 -100.00% | 0 0.00% of shares | low |
| Mar 2, 2026 | Pauling David Executive | Grant | Stock Option (right to buy) | — | +34K | 33,600 0.20% of shares | low |
| Mar 2, 2026 | Pauling David Executive | Grant | Restricted Stock Units (RSUs) | — | +4K | 4,200 0.03% of shares | low |
| Mar 2, 2026 | Pauling David Executive | Exercise | Restricted Stock Units (RSUs) | — | -2K -25.00% | 7,069 0.04% of shares | low |
| Mar 1, 2026 | Pauling David Executive | Exercise | Restricted Stock Units (RSUs) | — | -842 -33.31% | 1,686 0.01% of shares | low |
| Mar 1, 2026 | Pauling David Executive | Exercise | Restricted Stock Units (RSUs) | — | -500 -50.00% | 500 <0.01% of shares | low |
| Mar 2, 2026 | Gerber Hans-Peter Executive | Grant | Stock Option (right to buy) | — | +40K | 40,000 0.24% of shares | low |
| Mar 2, 2026 | Gerber Hans-Peter Executive | Grant | Restricted Stock Units (RSUs) | — | +5K | 5,000 0.03% of shares | low |
| Mar 2, 2026 | Gerber Hans-Peter Executive | Exercise | Restricted Stock Units (RSUs) | — | -3K -24.99% | 8,532 0.05% of shares | low |
| Mar 1, 2026 | Gerber Hans-Peter Executive | Exercise | Restricted Stock Units (RSUs) | — | -1K -33.33% | 2,250 0.01% of shares | low |
| Mar 2, 2026 | Chung Jane CEO | Grant | Stock Option (right to buy) | — | +175K | 175,000 1.06% of shares | low |
| Mar 2, 2026 | Chung Jane CEO | Grant | Restricted Stock Units (RSUs) | — | +40K | 40,000 0.24% of shares | low |
| Mar 2, 2026 | Chung Jane CEO | Exercise | Restricted Stock Units (RSUs) | — | -8K -25.00% | 23,250 0.14% of shares | low |
| Mar 1, 2026 | Chung Jane CEO | Exercise | Restricted Stock Units (RSUs) | — | -3K -33.33% | 5,000 0.03% of shares | low |
| Mar 1, 2026 | Chung Jane CEO | Exercise | Restricted Stock Units (RSUs) | — | -688 -50.00% | 688 <0.01% of shares | low |